Zacks Research Has Optimistic Outlook of AbbVie Q2 Earnings

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Zacks Research increased their Q2 2027 earnings estimates for AbbVie in a report issued on Thursday, September 18th. Zacks Research analyst Team now expects that the company will earn $3.85 per share for the quarter, up from their prior estimate of $3.84. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s FY2027 earnings at $15.25 EPS.

ABBV has been the subject of several other reports. Piper Sandler started coverage on AbbVie in a report on Tuesday, August 12th. They issued an “overweight” rating and a $231.00 price objective for the company. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price objective for the company in a report on Thursday, August 7th. Wells Fargo & Company increased their price target on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. JPMorgan Chase & Co. increased their price target on AbbVie from $200.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, August 25th. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $222.68.

AbbVie Stock Performance

Shares of AbbVie stock opened at $222.29 on Friday. The firm has a market capitalization of $392.69 billion, a P/E ratio of 105.85, a P/E/G ratio of 1.32 and a beta of 0.53. AbbVie has a 52 week low of $163.81 and a 52 week high of $223.49. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The firm’s 50 day moving average is $203.12 and its two-hundred day moving average is $195.01.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). The company had revenue of $15.42 billion during the quarter, compared to analysts’ expectations of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.65 earnings per share.

Institutional Trading of AbbVie

A number of hedge funds have recently added to or reduced their stakes in the business. Watts Gwilliam & Co. LLC boosted its stake in AbbVie by 2.8% in the 2nd quarter. Watts Gwilliam & Co. LLC now owns 16,830 shares of the company’s stock worth $3,124,000 after buying an additional 463 shares during the last quarter. Canal Capital Management LLC boosted its stake in AbbVie by 2.8% in the 2nd quarter. Canal Capital Management LLC now owns 5,579 shares of the company’s stock worth $1,036,000 after buying an additional 151 shares during the last quarter. Milestones Private Investment Advisors LLC acquired a new stake in AbbVie in the 2nd quarter worth about $240,000. NWF Advisory Services Inc. boosted its stake in AbbVie by 41.2% in the 2nd quarter. NWF Advisory Services Inc. now owns 13,504 shares of the company’s stock worth $2,507,000 after buying an additional 3,939 shares during the last quarter. Finally, American Trust boosted its stake in AbbVie by 36.8% in the 2nd quarter. American Trust now owns 23,890 shares of the company’s stock worth $4,434,000 after buying an additional 6,421 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares of the company’s stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be given a $1.64 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 312.38%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.